Info
Diálogo
Transferência

Avaliação Avaliações

Descrição:

RTOG 0825 Phase III GBM Salvage Treatment Summary Form (SF) Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5AE2A23C-8AF1-6A8B-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5AE2A23C-8AF1-6A8B-E044-0003BA3F9857

Palavras-chave:

Versões (4)

26/08/2012 26/08/2012 -
09/01/2015 09/01/2015 - Martin Dugas
09/01/2015 09/01/2015 - Martin Dugas
09/01/2015 09/01/2015 - Martin Dugas

Transferido a:

9 de janeiro de 2015

DOI:

Para um pedido faça login.

Licença :

Creative Commons BY-NC 3.0 Legacy

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Brain and Central Nervous System Tumors NCT00884741 Treatment - RTOG 0825 Phase III GBM Salvage Treatment Summary Form (SF) - 2797440v1.0

Inglês 1

Inglês

Detalhes

INSTRUCTIONS: Submit this form at the completion of each cycle of salvage treatment. Dates are to be recorded as mm-dd-yyyy unless otherwise specified

1 Formulários

StudyEvent: RTOG 0825 Phase III GBM Salvage Treatment Summary Form (SF)
1. INSTRUCTIONS: Submit this form at the completion of each cycle of salvage treatment. Dates are to be recorded as mm-dd-yyyy unless otherwise specified

Module 1

RTOG Study No.

Case #

Institution Name

Institution No.

Patient Initials

RTOG Patient ID

Amended Data (INSTRUCTIONS: Complete form on web to unblind the protocol treatment arm)

Yes

Assessment

Height (CM)

Weight (CM)

BSA (M2)

Karnofsky Performance Status (Use 9 if unknown)

Dead (0)

Moribund, Fatal Processes Progressing Rapidly (10)

Normal, No Complaints, No Evidence Of Disease (100)

Very Sick, Hospitalization Indicated. Death Not Imminent (20)

7 itens adicionais na visualização detalhada.

Neurologic function

Minor Neurologic Symptoms, Fully Active At Home/work Without Assistance (Minor neurologic symptoms, fully active at home/work without assistance)

Moderate Neurologic Symptoms, Fully Active At Home/work But Requires Assistance (Moderate neurologic symptoms, fully active at home/work but requires assistance)

Moderate Neurologic Symptoms, Less Than Fully Active At Home/work And Requires Assitance (Moderate neurologic symptoms, less than fully active at home/work and requires assistance)

No Neurologic Symptoms, Fully Active At Home/work Without Assistance (No neurologic symptoms, fully active at home/work without assistance)

Severe Neurologic Symptoms, Totally Inactive Requiring Complete Assistance At Home Or Institution, Unable To Work (Severe neurologic symptoms, totally inactive requiring complete assistance at home or institution, unable to work)

Unknown (Unknown)

Disease Progression

Salvage treatment being reported

Bevacizumab Alone (Bevacizumab alone)

Bevacizumab And Irinotecan (Bevacizumab and Irinotecan)

Bevacizumab And Tmz Salvage (Bevacizumab and TMZ salvage)

Is protocol chemotherapy continuing?

Yes

Unnamed 3

Agent Name

Agent Start Date (MM DD YYYY)

Agent End Date (MM DD YYYY)

Agent Total Dose (MG)

Total number of doses

Was dose reduced more than 20%

Yes

Reason for Treatment Modification

Adverse Event/side Effects/complications (Adverse event/side effects/complications)

Alternative Therapy (Alternative therapy)

Death On Study (Death on study)

Disease Progression, Relapse During Active Treatment (Disease progression, relapse during active treatment)

4 itens adicionais na visualização detalhada.

Reason Treatment Ended

Adverse Event/side Effects/complications (Adverse Event/Side Effects/Complications)

Alternative Therapy (Alternative therapy)

Death On Study (Death on study)

Disease Progression, Relapse During Active Treatment (Disease progression, relapse during active treatment)

5 itens adicionais na visualização detalhada.

Alternative therapy, specify

Other specify

Protocol Specific Adverse Event Evaluation

Were there any hemorrhage events during this report period

Yes

MedDRA Code

CTC Adverse Event Term

CTC AE Grade

CTCAE Begin Date (MM DD YYYY)

CTC AE Attribution Code

Definite (Definite)

Possible (Possible)

Probable (Probable)

Unlikely (Unlikely)

Unrelated (Unrelated)

CTC AE Attribution Code

Definite (Definite)

Possible (Possible)

Probable (Probable)

Unlikely (Unlikely)

Unrelated (Unrelated)

SAE report submitted

No (No)

Unknown (Unknown)

Yes (Yes)

SAE report submitted

No (No)

Unknown (Unknown)

Yes (Yes)

INR (International Normalized Ratio of prothrombin time Value)

INR LLN (Institution)

INR ULN (Institution)

PTT (sec) (Partial Thromboplastin Time Value)

PTT LLN (Institution)

seconds

PTT ULN (Institution)

seconds

PT (Prothrombin Time Value)

seconds

PT LLN (Institution)

seconds

PT ULN (Institution)

seconds

Platelets (PLT) (Platelets x 1000 cmm Value)

1000/uL

PLT LLN (Institution)

PLT ULN (Institution)

Date (MM DD YYYY)

Protocol Specific Adverse Event Evaluation

Were there any study-specific adverse events during this report period

Yes

CTC Adverse Event Term

CTC AE Grade

CTCAE Begin Date (MM DD YYYY)

CTC AE Attribution Code

Definite (Definite)

Possible (Possible)

Probable (Probable)

Unlikely (Unlikely)

Unrelated (Unrelated)

SAE report submitted

No (No)

Unknown (Unknown)

Yes (Yes)

Protocol Specific Adverse Event Evaluation

Any Treatment Related Adverse Events

No (No)

Unknown (Unknown)

Yes (Yes)

MedDRA Code

CTC Adverse Event Term

CTC AE Grade

CTCAE Begin Date (MM DD YYYY)

CTC AE Attribution Code

Definite (Definite)

Possible (Possible)

Probable (Probable)

Unlikely (Unlikely)

Unrelated (Unrelated)

SAE report submitted

No (No)

Unknown (Unknown)

Yes (Yes)

Footer Module

Comments

Signature of Person Completing This Form

Form Completion Date, Original

Voltar ao início da página

Similar models

Show recommended models

Descrição:

Link:

Palavras-chave:

Versões (4)

Transferido a:

DOI:

Licença :

Comentários do modelo :

Comentários do grupo de itens para :

Comentários do item para :

Brain and Central Nervous System Tumors NCT00884741 Treatment - RTOG 0825 Phase III GBM Salvage Treatment Summary Form (SF) - 2797440v1.0

INSTRUCTIONS: Submit this form at the completion of each cycle of salvage treatment. Dates are to be recorded as mm-dd-yyyy unless otherwise specified

Similar models

Contacto

Ajuda